Ricardo Figueiredo

Prof. Ricardo Figueiredo

Health, State University of Feira de Santana, Feira de Santana, Bahia, Brazil
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
RFRicardo Figueiredo
Ricardo Figueiredo
CPCecilia M Patino
Cecilia M Patino
JFJuliana CARVALHO FERREIRA
Juliana CARVALHO FERREIRA

14 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RFRicardo Figueiredo
Ricardo Figueiredo
GPGabriela P. Pinheiro
Gabriela P. Pinheiro
VAVanessa Arata
Vanessa Arata
MLMaisa F. M. Leal
Maisa F. M. Leal
CSCinthia V. N. Santana
Cinthia V. N. Santana
ÁCÁlvaro A. Cruz
Álvaro A. Cruz
Frailty assessment has been identified as critical approach in chronic respiratory diseases with substantial impact in the health status and functionality in later life. Aging modifies the immune response leading to a chronic pro-inflammatory state and increased susceptibility to airway infections. Since epigenetic changes, airway epithelium dysfunction and inflammatory cytokine activity seem to be more pronounced in the immunosenescence, elderly asthmatics are at higher risk of poor clinical outcomes. Therefore, we hypothesize that frailty would be associated with the degree of asthma control in elderly patients with moderate to severe asthma. The aims of this study are to investigate association between frailty and asthma control in patients over 60 years old to estimate the prevalence of frailty in this study population. We plan to conduct a cross-sectional study with at least 120 patients above 60 years old with diagnostic of moderate to severe asthma according to Global Initiative for Asthma (GINA) guidelines, treated at a referral outpatient clinic. We defined asthma control by the six-domain Asthma Control Questionnaire (ACQ-6) and frailty phenotype in accordance with Fried scale and visual scale of frailty (VS-Frailty). We hope to analyze the multidimensional relationships between frailty and asthma and contribute to innovative therapeutic plans in geriatric asthma.

21 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAElen Azevedo
Elen Azevedo
RFRicardo Figueiredo
Ricardo Figueiredo
RPRoberto Vieira Pinto
Roberto Vieira Pinto
TRTarsila de Carvalho Freitas Ramos
Tarsila de Carvalho Freitas Ramos
GSGeraldo Pedral Sampaio
Geraldo Pedral Sampaio
STSoraya Castro Trindade
Soraya Castro Trindade
This study investigated the systemic inflammatory response and mechanism of pulmonary lesions induced by Crotalus durissus cascavella venom in murine in the state of Bahia. In order to investigate T helper Th1, Th2 and Th17 lymphocyte profiles, we measured interleukin (IL) -2, IL-4, IL-6, IL-10, IL-17, tumor necrosis factor (TNF) and interferon gamma (IFN-γ) levels in the peritoneal fluid and macerated lungs of mice and histopathological alterations at the specific time windows of 1h, 3h, 6h, 12h, 24h and 48h after inoculation with Crotalus durissus cascavella venom. The data demonstrated an increase of acute-phase cytokines (IL-6 and TNF) in the first hours after inoculation, with a subsequent increase in IL-10 and IL-4, suggesting immune response modulation for the Th2 profile. The histopathological analysis showed significant morphological alterations, compatible with acute pulmonary lesions, with polymorphonuclear leukocyte (PMN) infiltration, intra-alveolar edema, congestion, hemorrhage and atelectasis. These findings advance our understanding of the dynamics of envenomation and contribute to improve clinical management and antiophidic therapy for individuals exposed to venom.

20 June 2023 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
RFRicardo Figueiredo
Ricardo Figueiredo
FHFernando Holguin
Fernando Holguin
MPMarcia Pizzichini
Marcia Pizzichini
GPGabriela Pimentel Pinheiro
Gabriela Pimentel Pinheiro
VAVanessa Arata
Vanessa Arata
JJJosé Bessa Junior
José Bessa Junior
To evaluate handgrip strength (HGS) as a diagnostic tool for frailty risk in elderly patients with asthma, as well as to investigate the prevalence of frailty in this population. Methods: This was a cross-sectional study including 96 patients = 60 years of age diagnosed with moderate to severe asthma and treated at a tertiary referral center in Brazil. We measured HGS using a calibrated hydraulic hand dynamometer. We used a frailty scale and the AUC to assess the diagnostic accuracy of the HGS test. Results: The median age of participants was 67 years. Most (78%) were women and non-White (91%) of low socioeconomic status. HGS identified those at risk for frailty, with an AUC of 71.6% (61.5-80.4%; p < 0.002), as well as a sensitivity of 73.58% and a specificity of 67.53%, on the basis of a cutoff of = 19 kgf. Conclusions: HGS appears to be a simple, reliable tool for clinicians to determine frailty risk in older asthma patients in a point-of-care setting.

Verified
Journal Article
Open access
PDF file
RFRicardo Figueiredo
Ricardo Figueiredo
RCRYAN DOS COSTA
RYAN DOS COSTA
CFCamila Figueiredo
Camila Figueiredo
ACAlvaro Augusto Cruz
Alvaro Augusto Cruz
Severe asthma is a multifactorial disorder with marked phenotypic heterogeneity and complex interactions between genetics and environmental risk factors, which could, at least in part, explain why during standard pharmacologic treatment, many patients remain poorly controlled and at an increased risk of airway remodeling and disease progression. The concept of “precision medicine” to better suit individual unique needs is an emerging trend in the management of chronic respiratory diseases. Over the past few years, Genome-Wide Association Studies (GWAS) have revealed novel pharmacogenetic variants related to responses to inhaled corticosteroids and the clinical efficacy of bronchodilators. Optimal clinical response to treatment may vary between racial/ethnic groups or individuals due to genetic differences. It is also plausible to assume that epigenetic factors play a key role in the modulation of gene expression patterns and inflammatory cytokines. Remarkably, specific genetic variants related to treatment effectiveness may indicate promising pathways for novel therapies in severe asthma. In this review, we provide a concise update of genetic determinants of poor response to treatment in severe asthma and future directions in the field.

RFRicardo Figueiredo
Ricardo Figueiredo
NDNathalia Filgueiras Vilaça Duarte
Nathalia Filgueiras Vilaça Duarte
DCDaniela Carla Barbosa Campos
Daniela Carla Barbosa Campos
MVManuel de Jesus Diaz Verduzco
Manuel de Jesus Diaz Verduzco
ÁMÁngel Alemán Márquez
Ángel Alemán Márquez
ARAdalberto Sperb Rubin
Adalberto Sperb Rubin
Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient’s journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.